SG/CALL/ASTRAZENECA/12000/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 15:41:06 2024-06-07 EDT | ||
| 1.1 EUR | -4.35% |
|
| Current month | +33.72% | ||
| 1 month | +27.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 1.1 | -4.35% |
| 24-06-06 | 1.15 | +2.68% |
| 24-06-05 | 1.12 | +8.74% |
| 24-06-04 | 1.03 | +5.10% |
| 24-06-03 | 0.98 | +13.95% |
Delayed Quote Deutsche Boerse AG
Last update June 07, 2024 at 03:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SU13YC |
| ISIN | DE000SU13YC4 |
| Date issued | 2023-11-13 |
| Strike | 12,000 p |
| Maturity | 2024-09-20 (105 Days) |
| Parity | 10 : 1 |
| Emission price | 0.5 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.18 € |
|---|---|
| Lowest since issue | 0.057 € |
| Spread | 0.1 € |
| Spread % | 8.40% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159.8
USD
Average target price
173.2
USD
Spread / Average Target
+8.39%
- Stock Market
- Warrants
- Warrant
